



Stand no 62

MBS unveils NEXTGENPCR revolution in thermal cycling at Festival of Genomics

Ramp rates of 1000 degrees per second shrink complete gene amplification to 10 minutes

Rotterdam, Netherlands, Feb 1, 2017: Dutch biotechnology company Molecular Biology Systems (MBS) today unveiled the pre-production model of its revolutionary new NEXTGENPCR thermal cycler at the Festival of Genomics in London. Described as the first real advance in thermal cycling for 15 years, the NEXTGENPCR dramatically reduces current time consuming DNA amplification from hours to minutes. As an example, Erasmus Medical Centre in the Netherlands recently reported having successfully amplified the complete BRCA1 gene (29 fragments) in less than 10 minutes using NEXTGENPCR.

The NEXTGENPCR cycler differs radically from previous thermal cyclers by employing 3 temperature zones with two heated blocks each. Zones are set to denaturing, extension and annealing temperatures. Standard microplates with samples embedded in polypropylene foil are

moved between zones, where they are slightly compressed by the temperature blocks. This ensures sample mixing and optimal heat transfer. Temperature transition is practically instantaneous.

“Until now attention has been focused on the sequencing and interpretation end of the genetic analysis chain,” says MBS CEO and founder Gert de Vos. “Amplification remains a necessary but incredibly time-consuming task. NEXTGENPCR changes all this – with ramp rates of MORE than 1000 degrees per second we can slash amplification times from hours to minutes and fit seamlessly into any lab routines and protocols. Since previewing NEXTGENPCR system towards the end of 2016, we have had major interest worldwide and are now in the process of establishing a dealer network with first orders due to ship in March.”

In addition to speed, NEXTGENPCR offers a range of other major benefits. Any plate format can be run – 24, 48, 96 or 384 well in the same machine (96 well plate available on launch, other plates as demand requires) . NEXTGENPCR operates both as a personal cycler or can be run in tandem using a robot for ultrahigh throughput work. Energy consumption is significantly reduced to 170 watts..

-ends-

For further information:
Gert de Vos, CEO
gertdevos@mbspcr.com
www.nextgenpcr.com

Media:
Richard Hayhurst

Richard@richardhayhurstassociates.com

Notes to editors:

Molecular Biology Systems (MBS) is a Netherlands-based molecular biology instrumentation company founded in 2015. The company's lead product is the NEXTGENPCR thermal cycler which uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes for both research and routine genetic testing. More at www.nextgenpcr.com